Shilpa Gupta, Director of Genitourinary Oncology at the Cleveland Clinic, shared on LinkedIn:
“Excited to see the PSMAddition trial published in The Lancet right on the heels of FDA approval of ¹⁷⁷Lu-PSMA-617 for patients with PSMA-positive metastatic hormone-sensitive prostate cancer.
Congrats Scott Tagawa, Michael Morris on leading this effort with the entire PSMAddition team!
Grateful to our patients who trusted us and made Cleveland Clinic the highest enrolling site in US!
Adding ¹⁷⁷Lu-PSMA-617 to ADT + ARPI lowers risk of radiographic progression or death by 28% (HR 0.72, p=0.002), with benefit held consistently across all subgroups.”
Title: [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Authors: Scott T Tagawa, Oliver Sartor, Josep M Piulats, Fred Saad, Karim Fizazi, Alison Reid, Himisha Beltran, Gero Kramer, Hakim Mahammedi, Matthias Eiber, Shilpa Gupta, Daniel Castellano, Ralph Hauke, Hyun Kim, Cheol Kwak, See Tong Pang, Philippe Barthélémy, Dong Dai, Jae Lyun Lee, Luke Nordquist, Russell Z Szmulewitz, Paweł Wiechno, Alejandro Yovine, Lauren Smith, Emmanuel Bouillaud, Olga Sakharova, Michael J Morris for the PSMAddition Investigators
Other articles featuring Shilpa Gupta on OncoDaily.